** Shares of Candel Therapeutics CADL.O down 17% to $8.13 post-market as co looks to raise equity after its stock popped this week
** Needham, Massachusetts-based firm launches $80 mln offering comprising stock and pre-funded warrants
** On Weds, CADL shares surged 68% to close at $7.75 after co said its prostate cancer therapy, CAN-2409, met main goal in late-stage study
** Stock finished up 26.5% at $9.80 on Thurs
** Co plans to use net offering proceeds to prepare submission of a Biologics License Application for CAN-2409, and for general purposes
** Citigroup, BofA and Canaccord Genuity jt bookrunners for offering
** With ~32.5 mln shares outstanding, co has roughly $320 mln market cap
** Stock ended 2023 at $1.47
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。